Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Filtros aplicados
Base de dados
Intervalo de ano de publicação
1.
Rev. esp. enferm. dig ; 105(4): 201-207, abr. 2013. tab
Artigo em Espanhol | IBECS | ID: ibc-113934

RESUMO

Introducción: la intolerancia a la histamina (IH) es una patología poco descrita en gastroenterología y que puede tener una sintomatología digestiva predominante. Los objetivos de este estudio son describir los casos diagnosticados en una consulta de gastroenterología pediátrica. Material y métodos: estudio observacional y retrospectivo analizando los pacientes diagnosticados de IH desde septiembre de 2010 a diciembre de 2011 en la consulta de gastroenterología pediátrica de un hospital terciario. Se consideraron con diagnóstico de IH al presentar 2 o más síntomas digestivos característicos, determinación de diaminooxidasa disminuida y/o respuesta a la dieta baja en histamina con pruebas de alergia IgE-mediada a alimentos negativos. Resultados: se han diagnosticado 16 pacientes. Hubo un predominio de niños (11/5) frente a las niñas. La edad media al inicio de los síntomas fue de 4 años (6 meses vs. 13 años y 6 meses) y la edad media al diagnóstico fue de 6 años y 6 meses (17 meses vs. 13 años y 11 meses). Los síntomas predominantes fueron dolor abdominal difuso (16/16), diarrea intermitente (10/16), cefalea (5/16) y vómitos intermitentes (4/16). Conclusiones: la intolerancia a la histamina es una patología poco conocida pero con una incidencia que puede ser relevante. Los síntomas predominantes son dolor abdominal difuso, diarrea, cefalea y vómitos de aparición crónica e intermitente. El diagnóstico se realiza por sospecha clínica, determinación de diaminooxidasa plasmática y respuesta a dieta baja en histamina. Con el tratamiento de dieta baja en histamina presentan una mejoría inmediata (AU)


Introduction: histamine intolerance (HI) is a poorly described disease in gastroenterology that may present with predominant digestive complaints. The goals of this study include a report of two cases diagnosed in a pediatric gastroenterology clinic. Material and methods: observational, retrospective study of patients diagnosed with HI from September 2010 to December 2011 at the pediatric gastroenterology clinic of a tertiary hospital. They were deemed to have a diagnosis of HI in the presence of 2 or more characteristic digestive complaints, decreased diamino oxidase (DAO) levels and/or response to a low histamine diet with negative IgE-mediated food allergy tests. Results: sixteen patients were diagnosed. Males predominated versus females (11/5). Mean age at symptom onset was 4 years (6 months vs. 13 years and 6 months) and mean age at diagnosis was 6 years and 6 months (17 months vs. 13 years and 11 months), with an interval of 2 years and 1 month between symptom onset and diagnosis (5 months vs. 4 years). Predominant symptoms included diffuse abdominal pain (16/16), intermittent diarrhea (10/16), headache (5/16), intermittent vomiting (4/16), and skin rash (2/16). The diagnosis was established by measuring plasma diamino oxidase levels, which were below 10 kU/L (normal > 10 kU/L) in 14 cases, and symptom clearance on initiating a low histamine diet. In two patients DAO levels were above 10 kU/L but responded to diet. Treatment was based on a diet low in histamine-contaning food, and antihistamines H1 y H2 had to be added for two cases. Conclusions: histamine intolerance is a little known disease with a potentially relevant incidence. Predominant complaints include diffuse abdominal pain, diarrhea, headache, and chronic intermittent vomiting. Its diagnosis is based on clinical suspicion, plasma DAO measurement, and response to a low histamine diet. Management with the latter provides immediate improvement (AU)


Assuntos
Humanos , Masculino , Feminino , Criança , Histamina/efeitos adversos , Hipersensibilidade Imediata/complicações , Hipersensibilidade Imediata/diagnóstico , Aminas Biogênicas , Hipersensibilidade Alimentar/complicações , Dor Abdominal/complicações , Dor Abdominal/etiologia , Cefaleia Histamínica/induzido quimicamente , Cefaleia Histamínica/complicações , Cefaleia Histamínica/diagnóstico , Estudos Retrospectivos , Hipersensibilidade Imediata/fisiopatologia , Imunoglobulina E , Técnicas Imunoenzimáticas/métodos , Técnicas Imunoenzimáticas , Transtornos da Alimentação e da Ingestão de Alimentos/complicações , Diarreia Infantil/complicações , Gastroenteropatias/complicações , Gastroenteropatias/diagnóstico , Cefaleia Histamínica/fisiopatologia
2.
An. R. Acad. Farm ; 78(4): 365-385, oct.-dic. 2012. ilus
Artigo em Espanhol | IBECS | ID: ibc-108440

RESUMO

La esquizofrenia es una enfermedad compleja que afecta a alrededor del 1% de la población mundial y constituye una de las más importantes causas de discapacidad crónica. Aunque su etiología es desconocida, la enfermedad implica diversas anomalías neuromorfológicas y neuroquímicas y se acepta que factores genéticos, bien solos o potenciados por factores ambientales y epigenéticos juegan un papel importante en su patogénesis. Numerosos estudios realizados durante los últimos cuarenta años han relacionado a alteraciones en la neurotransmisión mediada por aminas biógenas, la neurotransmisión glutamatérgica y gabaérgica con la patología de las psicosis esquizofrénicas. Recientemente, a través del conocimiento de genes de susceptibilidad así como de proteínas implicadas en la patología de la enfermedad, están permitiendo un diagnóstico precoz de la misma y el desarrollo de una nueva generación de compuestos que puedan actuar como antipsicóticos de una forma más selectiva(AU)


Schizophrenia is a complex disorder that affects about 1% of the world population and is one of the most important causes of chronic disability. Although its etiology is unknown, the disease involves various morphologic and neurochemical abnormalities and it it’s accepted that genetic factors, either alone or enhanced by environmental and epigenetic factors play a role in its pathogenesis. Numerous studies over the last forty years have involved alterations in biogenic amines mediated neurotransmission, GABA ergic and glutamatergic neurotransmission to the pathology of schizophrenic psychoses. Recently, the knowledge of susceptibility genes and proteins involved in the pathology of the disease, are allowing early diagnosis and the development of a new generation of compounds that can act as antipsychotics more selectively(AU)


Assuntos
Humanos , Patologia Molecular/métodos , Esquizofrenia/fisiopatologia , Antipsicóticos/uso terapêutico , Aminas Biogênicas/análise , Epigênese Genética , Predisposição Genética para Doença
3.
J. physiol. biochem ; 68(3): 447-454, sept. 2012. ilus
Artigo em Inglês | IBECS | ID: ibc-122332

RESUMO

Biogenic amines and polyamines participate in all vital organism functions, their levels being important function determinants. Studies were performed to check whether repeated administration of poly(propylene imine) (PPI) dendrimers, synthetic macromolecules with diaminobutane core, and peripheral primary amine groups, may influence the endogenous level of amines, as represented by the two of them: spermidine, a natural derivative of diaminobutane, and histamine. The experiment was carried out on Wistar rats. Fourth generation PPI dendrimer, as well as maltotriose-modified fourth generation PPI dendrimers with (a) cationic open sugar shell and (b) neutral dense sugar shell that possess a higher biocompatibility, was used. Applying the combination of column chromatography on Cellex P and spectrofluorimetric assays of o-phthaldialdehyde, the final amine condensation products were employed to analyze tissue spermidine and histamine outside the central nervous system. Furthermore, radioenzymatic assay was used to measure histamine levels in the brain. The obtained results indicate that in some tissues, the endogenous concentrations of histamine and spermidine may be affected by dendrimers depending on their dose and type of dendrimers (AU)


Assuntos
Animais , Ratos , Aminas Biogênicas/farmacocinética , Polipropilenos/farmacocinética , Dendrímeros/farmacocinética , Histamina/farmacocinética , Espermidina/farmacocinética
4.
J. physiol. biochem ; 63(2): 171-178, abr.-jun. 2007. graf
Artigo em Inglês | IBECS | ID: ibc-76674

RESUMO

Neurotoxic effects of methoxychlor (MTX) are poorly understood at present.This study was undertaken to evaluate the possible effects of MTX in norepinephrine,dopamine and amino acid contents and serotonin turnover in rat striatum. Forthis purpose, adult male Sprague-Dawley rats were administered 25 mg/kg/day ofMTX in sesame oil or vehicle only for 30 days. The neurotransmitters of interestwere measured in the striatum by HPLC. MTX decreased norepinephrine and 5-hydroxyindole acetic acid (5-HIAA) content and serotonin turnover (measured as 5-HIAA/serotonin ratio), and increased glutamate and GABA concentrations. However,the content of serotonin, aspartate, glutamine and taurine was not modified byMTX exposure. These data suggest that MTX exposure inhibits norepinephrine synthesisand serotonin metabolism. The inhibitory effect on norepinephrine could beexplained, at least in part, by the increase of both GABA and glutamate contents.Further studies are needed to understand the effects of MTX on serotonin. Also adisruptive effect of MTX on the metabolisms of glutamate, aspartate, glutamine andGABA emerges (AU)


No disponible


No disponible


Assuntos
Animais , Masculino , Ratos , Aminas Biogênicas/metabolismo , Corpo Estriado , Inseticidas/toxicidade , Metoxicloro/toxicidade , Neurotransmissores/metabolismo , Dopamina/metabolismo , Ácido Glutâmico/metabolismo , Ácido Hidroxi-Indolacético/metabolismo , Norepinefrina/metabolismo , Ratos Sprague-Dawley , Serotonina/metabolismo , Ácido gama-Aminobutírico/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...